Analyst Upgrades: The Coca-Cola Co, Amedisys Inc, and Sunrun Inc

Analysts upwardly revised their ratings and price targets on The Coca-Cola Co (KO), Amedisys Inc (AMED), and Sunrun Inc (RUN)

by Kirra Fedyszyn

Published on Mar 10, 2016 at 9:29 AM
Updated on Jun 24, 2020 at 10:16 AM

Analysts are weighing in on food and beverage stock The Coca-Cola Co (NYSE:KO), health care company Amedisys Inc (NASDAQ:AMED), and solar energy concern Sunrun Inc (NASDAQ:RUN). Here's a quick roundup of today's bullish brokerage notes on KO, AMED, and RUN.

  • KO is edging higher in electronic trading, thanks to a price-target increase to $51 from $47 at RBC. The Coca-Cola Co hit a one-year high of $44.83 on Wednesday, before closing at $44.81, and is now ahead 4.3% year-to-date. The stock could stand to benefit from further bullish analyst attention -- at present, 10 of 18 brokerage firms rate KO a "hold" or worse. Meanwhile, short-term option traders continue to be optimistic -- the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.37 is lower than 95% of all readings taken in the past year.
  • Oppenheimer raised its price target on AMED to $45 from $40, after the company reported better-than-expected fourth-quarter earnings earlier this week. Amedisys Inc has added 34% since hitting a year-to-date low of $32.18 in early February, and closed at $42.72 on Wednesday -- above their 200-day moving average for the first time since Jan. 22. While the stock has been a strong performer of late, speculative players have shown a preference for puts over calls. Specifically, AMED's SOIR of 1.41 sits in the 86th annual percentile.
  • Deutsche Bank initiated coverage on RUN with a "buy" rating and $15 price target -- a 126% premium over the stock's Wednesday close of $6.65, and in never-before-seen territory -- citing optimism over Sunrun Inc's cost structure, valuation, and business model. As a result, the shares, which have been on the mend since an early-February drop, are set to pop 5.3% at the open. The company is due to report quarterly earnings after the market closes tonight, and though three out of four analysts call RUN a "buy" or better, it appears a fair number of traders wouldn't mind a negative reaction -- 13% of the equity's available float is currently sold short, representing nearly seven sessions' worth of trading, at RUN's typical daily volume.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter